SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
Verismo Therapeutics
National Institutes of Health Clinical Center (CC)
ModeX Therapeutics, An OPKO Health Company
Poseida Therapeutics, Inc.
Dana-Farber Cancer Institute
LTZ Therapeutics, Inc.
Eli Lilly and Company
Virginia Commonwealth University
Masonic Cancer Center, University of Minnesota
Stichting Hemato-Oncologie voor Volwassenen Nederland
Memorial Sloan Kettering Cancer Center
GenomeFrontier Therapeutics TW Co., Ltd.
H. Lee Moffitt Cancer Center and Research Institute
University of Arizona
Mayo Clinic
Memorial Sloan Kettering Cancer Center
University of Nebraska
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Insel Gruppe AG, University Hospital Bern
Florida International University
Masonic Cancer Center, University of Minnesota
Shanghai Exuma Biotechnology Ltd.
City of Hope Medical Center
Masonic Cancer Center, University of Minnesota
Pell Bio-Med Technology Co., Ltd.
ImmunityBio, Inc.
The First Affiliated Hospital of Xiamen University
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Nkarta, Inc.
Ruijin Hospital
Zhejiang Provincial People's Hospital
Australasian Leukaemia and Lymphoma Group
Juno Therapeutics, a Subsidiary of Celgene
Sunnybrook Health Sciences Centre
City of Hope Medical Center
Celgene
Athenex, Inc.
Florida International University
Atara Biotherapeutics
Centre Hospitalier Universitaire, Amiens
Roswell Park Cancer Institute
Rush University Medical Center
Stanford University
Swiss Cancer Institute
National Institutes of Health Clinical Center (CC)
Rutgers, The State University of New Jersey
Gilead Sciences
Roswell Park Cancer Institute
University of South Florida
Roswell Park Cancer Institute